{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:16:11Z","timestamp":1767777371969,"version":"3.46.0"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glutamate is the major excitatory amino acid in the mammalian CNS and is involved in transmission of pain together with processes for cognition, memory and learning. In order to terminate glutamatergic neurotransmission and avoid excitotoxic damage, a balanced glutamate homeostasis is of critical importance. The level of glutamate in the synaptic cleft is regulated through the action of five subtypes of excitatory amino acid transporters (EAAT1-5). Ceftriaxone, a \u03b2-lactam, induces EAAT-2 and has proven effect for the treatment of neuropathic pain. This pilot study investigated the effects of ceftriaxone upon acute and inflammatory pain and additionally, the analgesic effect of ceftriaxone after introduction of neuropathic pain.<\/jats:p>\n                  <jats:sec id=\"j_j.sjpain.2011.03.003_s_001\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Rats were tested before, during and after treatment of ceftriaxone for changes in response to both mechanical and thermal stimuli, using calibrated von Frey filaments and Hargreaves instrument, respectively. Inflammatory responses were investigated by assessing the response to intra-plantar injections of formalin; lastly, neuropathic pain was introduced using the spinal nerve ligation (SNL) model after which changes in both mechanical and thermal responses were again investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2011.03.003_s_002\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A significant increase in mechanical withdrawal threshold was observed following acute pain inducement in ceftriaxone treated rats. A marked increase in thermal withdrawal latency was also observed. In response to intra plantar administered formalin, ceftriaxone delayed the intensity of nocifensive behaviours. Applying the SNL model of neuropathic pain on naive rats created significant mechanical allodynia, but only a negligibly different response to thermal stimulation. After treatment with ceftriaxone the treated rats developed a hypoalgesic response to thermal stimulation, whilst the response to mechanical pain was insignificant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2011.03.003_s_003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In conclusion, ceftriaxone clearly interfered in the transmission of noxious signalling and proved in this study to have an effect upon acute\n                      <jats:italic>thermal and mechanical<\/jats:italic>\n                      pain thresholds as well as pathologic pain conditions. The present results are a piece in the large puzzle where administration route, dosage and pain models must be thoroughly investigated before a study can be planned for a proof of concept in different clinical pain states.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2011.03.003_s_004\">\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>The current study demonstrates that ceftriaxone has a mitigating effect upon many pain modalities including acute and inflammatory, and that these modalities should be included in future studies characterising the anti-nociceptive effect of beta-lactams such as ceftriaxone. The fact that \u03b2-lactams also has antibiotic properties implies that similar chemical structures could be identified with the positive effect upon expression levels of EAAT2, but lacking the antibiotic side effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.sjpain.2011.03.003","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T15:50:44Z","timestamp":1309967444000},"page":"132-136","source":"Crossref","is-referenced-by-count":15,"title":["Effects of the excitatory amino acid transporter subtype 2 (EAAT-2) inducerceftriaxone on different pain modalities in rat"],"prefix":"10.1515","volume":"2","author":[{"given":"Laila","family":"Eljaja","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences , University of Copenhagen , Universitetsparken 2, DK-2100 Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole J.","family":"Bjerrum","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences , University of Copenhagen , Universitetsparken 2, DK-2100 Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per Hartvig","family":"Honor\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences , University of Copenhagen , Universitetsparken 2, DK-2100 Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjarke","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences , University of Copenhagen , Universitetsparken 2, DK-2100 Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2011,7,1]]},"reference":[{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_001","doi-asserted-by":"crossref","unstructured":"Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433(7021):73-7.","DOI":"10.1038\/nature03180"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_002","doi-asserted-by":"crossref","unstructured":"Hu Y, Li W, Lu L, Cai J, Xian X, Zhang M, Li Q, Li L. An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. Pain 2010;148(2):284-301.","DOI":"10.1016\/j.pain.2009.11.014"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_003","doi-asserted-by":"crossref","unstructured":"Arriza JL, Eliasof S, Kavanaugh MP, Amara SG. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci U S A 1997;94(8):4155-60.","DOI":"10.1073\/pnas.94.8.4155"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_004","doi-asserted-by":"crossref","unstructured":"Arriza JL, Kavanaugh MP, Fairman WA,Wu YN, Murdoch GH, North RA, Amara SG. Cloning and expression of a human neutral amino acid transporter with structural similarity to the glutamate transporter gene family. J Biol Chem 1993;268(21):15329-32.","DOI":"10.1016\/S0021-9258(18)82257-8"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_005","doi-asserted-by":"crossref","unstructured":"Fairman WA, Vandenberg RJ, Arriza JL, Kavanaugh MP, Amara SG. An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature 1995;375(6532):599-603.","DOI":"10.1038\/375599a0"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_006","doi-asserted-by":"crossref","unstructured":"Kanai Y, Hediger MA. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 1992;360(6403):467-71.","DOI":"10.1038\/360467a0"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_007","doi-asserted-by":"crossref","unstructured":"Bridges RJ, Esslinger CS. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 2005;107(3):271-85.","DOI":"10.1016\/j.pharmthera.2005.01.002"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_008","doi-asserted-by":"crossref","unstructured":"Seal RP, Amara SG. Excitatory amino acid transporters: a family in flux. Annu Rev Pharmacol Toxicol 1999;39:431-56.","DOI":"10.1146\/annurev.pharmtox.39.1.431"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_009","doi-asserted-by":"crossref","unstructured":"Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997;276(5319):1699-702.","DOI":"10.1126\/science.276.5319.1699"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_010","doi-asserted-by":"crossref","unstructured":"Beart PM, O\u2019Shea RD. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol 2007;150(1):5-17.","DOI":"10.1038\/sj.bjp.0706949"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_011","doi-asserted-by":"crossref","unstructured":"Niederberger E, Schmidtko A, Rothstein JD, Geisslinger G, Tegeder I. Modulation of spinal nociceptive processing through the glutamate transporter GLT-1. Neuroscience 2003;116(1):81-7.","DOI":"10.1016\/S0306-4522(02)00547-X"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_012","doi-asserted-by":"crossref","unstructured":"Zagami CJ, Beart PM, Wallis N, Nagley P, O\u2019Shea RD. Oxidative and excitotoxic insults exert differential effects on spinal motoneurons and astrocytic glutamate transporters: Implications for the role of astrogliosis in amyotrophic lateral sclerosis. Glia 2009;57(2):119-35.","DOI":"10.1002\/glia.20739"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_013","doi-asserted-by":"crossref","unstructured":"Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 2003;23(7):2899-910.","DOI":"10.1523\/JNEUROSCI.23-07-02899.2003"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_014","doi-asserted-by":"crossref","unstructured":"Xin WJ, Weng HR, Dougherty PM. Plasticity in expression of the glutamate transporters GLT-1 and GLAST in spinal dorsal horn glial cells following partial sciatic nerve ligation. Mol Pain 2009;5:15.","DOI":"10.1186\/1744-8069-5-15"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_015","doi-asserted-by":"crossref","unstructured":"Liaw WJ, Stephens Jr RL, Binns BC, Chu Y, Sepkuty JP, Johns RA, Rothstein JD, Tao YX. Spinal glutamate uptake is critical for maintaining normal sensory transmission in rat spinal cord. Pain 2005;115(1-2):60-70.","DOI":"10.1016\/j.pain.2005.02.006"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_016","doi-asserted-by":"crossref","unstructured":"Niederberger E, Schmidtko A, Coste O, Marian C, Ehnert C, Geisslinger G. The glutamate transporter GLAST is involved in spinal nociceptive processing. Biochem Biophys Res Commun 2006;346(2):393-9.","DOI":"10.1016\/j.bbrc.2006.05.163"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_017","doi-asserted-by":"crossref","unstructured":"Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, Volsky DJ, Fisher PB. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008;283(19):13116-23.","DOI":"10.1074\/jbc.M707697200"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_018","doi-asserted-by":"crossref","unstructured":"Lin Y, Tian G, Roman K, Handy C, Travers JB, Lin CL, Stephens RLJr. Increased glial glutamate transporter EAAT2 expression reduces visceral nociceptive response in mice. Am J Physiol Gastrointest Liver Physiol 2009;296(1):G129-34.","DOI":"10.1152\/ajpgi.90556.2008"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_019","doi-asserted-by":"crossref","unstructured":"Ramos KM, Lewis MT,Morgan KN, Crysdale NY, Kroll JL, Taylor FR, Harrison JA, Sloane EM, Maier SF, Watkins LR. Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience 2010;169(4):1888-900.","DOI":"10.1016\/j.neuroscience.2010.06.014"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_020","doi-asserted-by":"crossref","unstructured":"Zhang B, Tao F, Liaw WJ, Bredt DS, Johns RA, Tao YX. Effect of knock down of spinal cord PSD-93\/chapsin-110 on persistent pain induced by complete Freund\u2019s adjuvant and peripheral nerve injury. Pain 2003;106(1-2):187-96.","DOI":"10.1016\/j.pain.2003.08.003"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_021","doi-asserted-by":"crossref","unstructured":"Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53(1):55-63.","DOI":"10.1016\/0165-0270(94)90144-9"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_022","doi-asserted-by":"crossref","unstructured":"Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980;20:441-62.","DOI":"10.1146\/annurev.pa.20.040180.002301"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_023","doi-asserted-by":"crossref","unstructured":"Drew LJ, Rugiero F, Cesare P, Gale JE, Abrahamsen B, Bowden S, Heinzmann S, Robinson M, Brust A, Colless B, Lewis RJ,WoodJN. High-threshold mechanosensitive ion channels blocked by a novel conopeptide mediate pressure-evoked pain. PLoS One 2007;2(6):e515.","DOI":"10.1371\/journal.pone.0000515"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_024","doi-asserted-by":"crossref","unstructured":"Ekberg J, Jayamanne A, Vaughan CW, Aslan S, Thomas L, Mould J, Drinkwater R, Baker MD, Abrahamsen B, Wood JN, Adams DJ, Christie MJ, Lewis RJ. muO-conotoxin  MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci U S A 2006;103(45):17030\u20135.","DOI":"10.1073\/pnas.0601819103"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_025","doi-asserted-by":"crossref","unstructured":"Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50(3):355-63.","DOI":"10.1016\/0304-3959(92)90041-9"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_026","doi-asserted-by":"crossref","unstructured":"Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992;51(1):5-17.","DOI":"10.1016\/0304-3959(92)90003-T"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_027","doi-asserted-by":"crossref","unstructured":"Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review. Brain Res 2004;1000(1-2):40-56.","DOI":"10.1016\/j.brainres.2003.10.073"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_028","doi-asserted-by":"crossref","unstructured":"Larsson M. Ionotropic glutamate receptors in spinal nociceptive processing. Mol Neurobiol 2009;40(3):260-88.","DOI":"10.1007\/s12035-009-8086-8"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_029","doi-asserted-by":"crossref","unstructured":"Liu XJ, Salter MW. Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn. Eur J Neurosci 2010.","DOI":"10.1111\/j.1460-9568.2010.07351.x"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_030","doi-asserted-by":"crossref","unstructured":"Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin Cell Dev Biol 2006;17(5):592-604.","DOI":"10.1016\/j.semcdb.2006.10.008"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_031","doi-asserted-by":"crossref","unstructured":"Dowdall T, Robinson I, Meert TF. Comparison of five different rat models of peripheral nerve injury. Pharmacol Biochem Behav 2005;80(1):93-108.","DOI":"10.1016\/j.pbb.2004.10.016"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_032","doi-asserted-by":"crossref","unstructured":"Hogan Q. Animal pain models. Reg Anesth Pain Med 2002;27(4):385-401.","DOI":"10.1097\/00115550-200207000-00009"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_033","doi-asserted-by":"crossref","unstructured":"Kim KJ, Yoon YW, Chung JM. Comparison of three rodent neuropathic pain models. Exp Brain Res 1997;113(2):200-6.","DOI":"10.1007\/BF02450318"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_034","doi-asserted-by":"crossref","unstructured":"Secko D. Antibiotics that protect the brain. CMAJ 2005;172(4):467-8.","DOI":"10.1503\/cmaj.050022"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_035","doi-asserted-by":"crossref","unstructured":"Storck T, Schulte S, Hofmann K, Stoffel W. Structure, expression, and functional analysis of a Na(+)-dependent glutamate\/aspartate transporter from rat brain. Proc Natl Acad Sci U S A 1992;89(22):10955-9.","DOI":"10.1073\/pnas.89.22.10955"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_036","doi-asserted-by":"crossref","unstructured":"Tao YX, Gu J, Stephens Jr RL. Role of spinal cord glutamate transporter during normal sensory transmission and pathological pain states. Mol Pain 2005; 1:30.","DOI":"10.1186\/1744-8069-1-30"},{"key":"2025120909574028660_j_j.sjpain.2011.03.003_ref_037","doi-asserted-by":"crossref","unstructured":"Weng HR, Chen JH, Cata JP. Inhibition of glutamate uptake in the spinal cord induces hyperalgesia and increased responses of spinal dorsal horn neurons to peripheral afferent stimulation. Neuroscience 2006;138(4):1351-60.","DOI":"10.1016\/j.neuroscience.2005.11.061"}],"container-title":["Scandinavian Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/sjpain\/2\/3\/article-p132.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1877886011000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1877886011000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2011.03.003\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2011.03.003\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:09:22Z","timestamp":1765282162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2011.03.003\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7,1]]}},"alternative-id":["10.1016\/j.sjpain.2011.03.003"],"URL":"https:\/\/doi.org\/10.1016\/j.sjpain.2011.03.003","relation":{},"ISSN":["1877-8860","1877-8879"],"issn-type":[{"type":"print","value":"1877-8860"},{"type":"electronic","value":"1877-8879"}],"subject":[],"published":{"date-parts":[[2011,7,1]]}}}